TITLE IX

PHARMACOVIGILANCE
CHAPTER 2

Transparency and communications
Article 106
Each Member State shall set up and maintain a national medicines web-portal which shall be linked to the European medicines web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004. By means of the national medicines web-portals, the Member States shall make publicly available at least the following:
1. public assessment reports, together with a summary thereof;
2. summaries of product characteristics and package leaflets;
3. summaries of risk management plans for medicinal products authorised in accordance with this Directive;
4. the list of medicinal products referred to in Article 23 of Regulation (EC) No 726/2004;
5. information on the different ways of reporting suspected adverse reactions to medicinal products to national competent authorities by healthcare professionals and patients, including the web-based structured forms referred to in Article 25 of Regulation (EC) No 726/2004.
Substituted by Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance).